Data / Drug companies / Publix Super Markets Inc
Publix Super Markets Inc: 152 products in the FDA NDC directory, labeler code 56062
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Publix Super Markets Inc (labeler code 56062) lists 152 products in the FDA National Drug Code Directory, covering 78 finished drugs by generic name. By type: 152 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on July 15, 2026.
The request: Watch Publix Super Markets Inc (FDA labeler code 56062): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 56062
- Products in commercial distribution
- 152
- Packages
- 213
- Finished drugs by generic name
- 78
- Prescription products
- 0
- Over the counter products
- 152
- Flagged as original packager
- 146 of 146 products that carry the flag
- Started marketing in the last 12 months
- 17
- Products with a marketing end date set
- 10
- Earliest marketing start
- September 15, 1988
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 76 | 50% |
| Generic drugs (ANDA) | 71 | 46.7% |
| New drug applications (NDA) | 5 | 3.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 152 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 16 | 10.5% |
| Solution | 15 | 9.9% |
| Gum, chewing | 12 | 7.9% |
| Lozenge | 10 | 6.6% |
| Suspension | 9 | 5.9% |
| Capsule, liquid filled | 7 | 4.6% |
| Tablet, chewable | 7 | 4.6% |
| Tablet, film coated, extended release | 6 | 3.9% |
| Tablet | 6 | 3.9% |
| Gel | 6 | 3.9% |
| Mouthwash | 6 | 3.9% |
| Tablet, coated | 6 | 3.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Cetirizine HCl | 56062-495 | Capsule | New drug applications (NDA) | July 15, 2026 |
| Nicotine | 56062-957 | Lozenge | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-812 | Gum, chewing | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-734 | Lozenge | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine coated | 56062-681 | Lozenge | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-671 | Lozenge | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-646 | Gum, chewing | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-636 | Lozenge | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine coated | 56062-543 | Lozenge | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-509 | Lozenge | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-499 | Lozenge | Generic drugs (ANDA) | June 11, 2026 |
| Coated nicotine | 56062-369 | Gum, chewing | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-298 | Gum, chewing | Generic drugs (ANDA) | June 11, 2026 |
| Nicotine | 56062-019 | Gum, chewing | Generic drugs (ANDA) | June 11, 2026 |
| Nasal and chest decongestant | 56062-614 | Tablet, multilayer, extended release | Generic drugs (ANDA) | April 2, 2026 |
| Cetylpyridinium Chloride | 56062-542 | Liquid | Over the counter monograph drugs | March 11, 2026 |
| Acid reducer | 56062-088 | Tablet, film coated | Generic drugs (ANDA) | March 6, 2026 |
| Arthritis pain reliever | 56062-471 | Gel | Generic drugs (ANDA) | September 12, 2025 |
| Coated nicotine | 56062-110 | Gum, chewing | Generic drugs (ANDA) | September 5, 2025 |
| Childrens cold cough dm | 56062-502 | Solution | Over the counter monograph drugs | July 28, 2025 |
| Dual action | 56062-530 | Tablet, film coated | Generic drugs (ANDA) | May 16, 2025 |
| Sleep aid | 56062-441 | Tablet | Generic drugs (ANDA) | May 16, 2025 |
| Allergy | 56062-923 | Tablet, film coated | Over the counter monograph drugs | April 28, 2025 |
| Nitetime severe | 56062-763 | Solution | Over the counter monograph drugs | February 3, 2025 |
| Nighttime Sleep Aid | 56062-091 | Tablet, coated | Over the counter monograph drugs | November 25, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.